Efficacy and Safety of TD-1473 in Crohn's Disease

Summary

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

Timeline

Start

2018-11-19

Primary completion

2021-12-30

Completion

2021-12-30

Outcome

Outcome not reported

Stopped: “The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.”

Drugs

Indications